CMML
16
1
4
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
6.3%
1 terminated out of 16 trials
90.9%
+4.4% vs benchmark
6%
1 trials in Phase 3/4
40%
4 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (16)
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML
Haplo Peripheral Blood Sct In GVHD Prevention
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
Ascorbic Acid Levels in MDS, AML, and CMML Patients
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations